In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.

Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...

Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital orga ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study paramet ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...